Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Recombinant Vaccines Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Recombinant Vaccines Industry
  • 1.7 COVID-19 Impact: Recombinant Vaccines Market Trends

    • 2 Global Recombinant Vaccines Quarterly Market Size Analysis

    • 2.1 Recombinant Vaccines Business Impact Assessment - COVID-19
      • 2.1.1 Global Recombinant Vaccines Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Recombinant Vaccines Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Recombinant Vaccines Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Recombinant Vaccines Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Recombinant Vaccines Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Recombinant Vaccines Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Recombinant Vaccines Market
    • 3.5 Key Manufacturers Recombinant Vaccines Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Recombinant Vaccines Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Subunit Recombinant Vaccines
      • 1.4.2 Attenuated Recombinant Vaccines
      • 1.4.3 Vector Recombinant Vaccines
    • 4.2 By Type, Global Recombinant Vaccines Market Size, 2019-2021
      • 4.2.1 By Type, Global Recombinant Vaccines Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Recombinant Vaccines Price, 2020-2021

    5 Impact of Covid-19 on Recombinant Vaccines Segments, By Application

    • 5.1 Overview
      • 5.5.1 Recombinant Human Vaccines
      • 5.5.2 Animal Recombinant Vaccines
    • 5.2 By Application, Global Recombinant Vaccines Market Size, 2019-2021
      • 5.2.1 By Application, Global Recombinant Vaccines Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Recombinant Vaccines Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Merck & Co., Inc
      • 7.1.1 Merck & Co., Inc Business Overview
      • 7.1.2 Merck & Co., Inc Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.1.3 Merck & Co., Inc Recombinant Vaccines Product Introduction
      • 7.1.4 Merck & Co., Inc Response to COVID-19 and Related Developments
    • 7.2 Green Cross Corporation
      • 7.2.1 Green Cross Corporation Business Overview
      • 7.2.2 Green Cross Corporation Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.2.3 Green Cross Corporation Recombinant Vaccines Product Introduction
      • 7.2.4 Green Cross Corporation Response to COVID-19 and Related Developments
    • 7.3 Pfizer Inc.
      • 7.3.1 Pfizer Inc. Business Overview
      • 7.3.2 Pfizer Inc. Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.3.3 Pfizer Inc. Recombinant Vaccines Product Introduction
      • 7.3.4 Pfizer Inc. Response to COVID-19 and Related Developments
    • 7.4 Bayer AG
      • 7.4.1 Bayer AG Business Overview
      • 7.4.2 Bayer AG Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.4.3 Bayer AG Recombinant Vaccines Product Introduction
      • 7.4.4 Bayer AG Response to COVID-19 and Related Developments
    • 7.5 Sanofi S A.
      • 7.5.1 Sanofi S A. Business Overview
      • 7.5.2 Sanofi S A. Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.5.3 Sanofi S A. Recombinant Vaccines Product Introduction
      • 7.5.4 Sanofi S A. Response to COVID-19 and Related Developments
    • 7.6 Protein Science Corporation
      • 7.6.1 Protein Science Corporation Business Overview
      • 7.6.2 Protein Science Corporation Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.6.3 Protein Science Corporation Recombinant Vaccines Product Introduction
      • 7.6.4 Protein Science Corporation Response to COVID-19 and Related Developments
    • 7.7 GlaxoSmithKline Plc.
      • 7.7.1 GlaxoSmithKline Plc. Business Overview
      • 7.7.2 GlaxoSmithKline Plc. Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Product Introduction
      • 7.7.4 GlaxoSmithKline Plc. Response to COVID-19 and Related Developments
    • 7.8 Novartis AG
      • 7.8.1 Novartis AG Business Overview
      • 7.8.2 Novartis AG Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.8.3 Novartis AG Recombinant Vaccines Product Introduction
      • 7.8.4 Novartis AG Response to COVID-19 and Related Developments
    • 7.9 Bharat Biotech
      • 7.9.1 Bharat Biotech Business Overview
      • 7.9.2 Bharat Biotech Recombinant Vaccines Quarterly Production and Revenue, 2020
      • 7.9.3 Bharat Biotech Recombinant Vaccines Product Introduction
      • 7.9.4 Bharat Biotech Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Recombinant Vaccines Supply Chain Analysis
      • 8.1.1 Recombinant Vaccines Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Recombinant Vaccines Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Recombinant Vaccines Distribution Channels
      • 8.2.2 Covid-19 Impact on Recombinant Vaccines Distribution Channels
      • 8.2.3 Recombinant Vaccines Distributors
    • 8.3 Recombinant Vaccines Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Recombinant Vaccines, including the following market information:
      Global Recombinant Vaccines Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Recombinant Vaccines Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Recombinant Vaccines Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Recombinant Vaccines Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

      Key market players
      Major competitors identified in this market include Merck & Co., Inc, Green Cross Corporation, Pfizer Inc., Bayer AG, Sanofi S A., Protein Science Corporation, GlaxoSmithKline Plc., Novartis AG, Bharat Biotech, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Subunit Recombinant Vaccines
      Attenuated Recombinant Vaccines
      Vector Recombinant Vaccines

      Based on the Application:
      Recombinant Human Vaccines
      Animal Recombinant Vaccines

      Buy now